Hyderabad: Bharat Biotech International Limited is now in the process of bringing out a vaccine against tuberculosis. The country's leading vaccine manufacturer will be signing an MoU with another firm for technology exchange.
"Our honourable Prime Minister (Narendra Modi) has got an agenda of 2025 for the eradication of tuberculosis. I think we are in that direction. But we don't have the technology so we are partnering with somebody else. On that matter we should be announcing soon," Krishna Ella, Chairman and Managing Director of Bharat Biotech said in a panel discussion as part of BioAsia 2022 on Thursday. Krishna Ella said that the TB vaccine is currently undergoing phase 3 clinical trials.
The immunology of the nasal vaccine being developed by the company against COVID-19 has been established, he mentioned.
Last month Bharat Biotech received approval for phase 3 clinical trials of BBV154 (Nasal vaccine). The company will evaluate the jab for both the two-dose primary schedule and booster dose schedule.
Also Read: Over 70% adolescents in 15-18 age group given first dose of Bharat Biotech's Covaxin
